Idarubicin inhibits CYP450 2D6. Idarubicin is about 57.5-fold and 25-fold more active than doxorubicin and epirubicin, respectively. Idarubicin is able to overcome P-glycoprotein-mediated multidrug resistance. The high stereospecificity in Idarubicin reduction might result from chiral induction due to the presence of asymmetric centres near to the carbonyl group in Idarubicin.
| Molecular Weight | 533.95 |
| Formula | C26H27NO9.HCl |
| CAS Number | 57852-57-0 |
| Solubility (25°C) | DMSO 60 mg/mL Water 6 mg/mL |
| Storage | 2-8°C, dry, protect from light, sealed |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
| Related Topoisomerase Products |
|---|
| ICRF-193
ICRF-193 is an TopoII inhibitor. |
| Topoisomerase II inhibitor 15
Topoisomerase II inhibitor 15 is a Topoisomerase II inhibitor. |
| Topoisomerase II inhibitor 13
Topoisomerase II inhibitor 13 is a topoisomerase II (Topo II) inhibitor. |
| ICRF-196
ICRF-196 is an racemic mixture of the (S,S)- and (R,R)-isomers of ICRF-193. |
| Cholesteryl hemisuccinate
Cholesteryl hemisuccinate is a with hepatoprotective an anticancer activity. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
